Carson K R, Bates M L, Tomasson M H
Division of Oncology, Department of Medicine, Washington University School of Medicine, St Louis, MO, USA.
Department of Pediatrics, Critical Care Division and the John Rankin Laboratory of Pulmonary Medicine, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA.
Bone Marrow Transplant. 2014 Aug;49(8):1009-15. doi: 10.1038/bmt.2014.71. Epub 2014 May 12.
Despite tremendous advances in treatments for myeloma in the past decade, the disease remains incurable in the majority of patients. Here, we review recent data demonstrating an association between obesity and increased risk of myeloma development. This may be due to the pro-inflammatory cytokine profile caused by obesity. Currently, there are no screening or prevention strategies for myeloma, but we propose that obesity-associated inflammatory pathways, or obesity itself, may be amenable to intervention, thereby preventing the transition from pre-malignancy to myeloma. In addition, we suggest that the morbidity, mortality and the significant costs associated with myeloma treatment could be reduced by addressing modifiable risk factors, and that research efforts should explore this novel hypothesis.
尽管在过去十年中骨髓瘤的治疗取得了巨大进展,但大多数患者的疾病仍无法治愈。在此,我们回顾了最近的数据,这些数据表明肥胖与骨髓瘤发生风险增加之间存在关联。这可能是由于肥胖引起的促炎细胞因子谱所致。目前,尚无骨髓瘤的筛查或预防策略,但我们提出与肥胖相关的炎症途径或肥胖本身可能适合进行干预,从而预防从癌前病变向骨髓瘤的转变。此外,我们建议通过解决可改变的风险因素来降低与骨髓瘤治疗相关的发病率、死亡率和巨大成本,并且研究工作应探索这一新的假设。